Lapatinib

Dual EGFR/ERBB2 inhibitor used as a treatment for breast cancer. The dissociation of Lapatinib from the protein requires more than 5 hours, potentiating drug efficacy. Feel free to use this image, just link to www.enzymlogic.com.

Done